Our goal is to empower very early screening of genetic and infectious diseases. By lowering the detection limit of rare mutations and pathogens, we are looking to catch diseases while they are still treatable. Our assay technology platforms will enable sensitive, rapid, and affordable point-of-care testing.
We are thrilled to announce @GenEndeavor will be presenting at the upcoming BIO-Europe Spring Conference in Barcelona, Spain on March 19, 2024.
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.
"Joining GenEndeavor fills me with excitement as I look forward to immersing myself in molecular diagnostics and making significant contributions to tackling practical challenges." - Brindhi Amalraj
We are thrilled to announce @GenEndeavor’s participation in the upcoming BIO CEO & Investor Conference, in New York City, NY, on February 26-27, 2024.
At the event, GenEndeavor will showcase our Non-Enzymatic Amplification Technologies (NEAT) platform to usher in a new generation of technologies for molecular diagnostics.
Despite some incredible progress made in cancer research in the last several years, sadly, advanced stage ovarian cancer still results in a 17% survival rate. This means that there are no screening tests available for the nearly 4 billion women in the world.
As we approach the end of the year, we at @GenEndeavor continue to think about the challenges that persist in women's healthcare. Despite some incredible progress made in cancer research, sadly, advanced stage ovarian cancer still results in a 17% survival rate.
It was my pleasure to present GenEndeavor’s approach to developing an early-detection ovarian cancer screening test at the MedInvest Oncology Investor conference this week.
Advanced stage ovarian cancer has a survival rate of 17% and yet, today, there is still no screening test for the nearly 4 billion women on the planet. The reason for this is existing technologies lack the combined sensitivity and specificity to detect cancer biomarkers at very early stages when the disease is still treatable and advancement to later stages can be prevented.
